Therefore, picornavirus vaccine strategies should be considered an attractive option for cancer therapeutics, as picornaviruses engineered to express tumor antigens have oncolytic properties and enhance antitumor immunity, which improves the tumor antigen-specific CD8 T cell response. This evidence concerns the gene CD8A and neoplasm.